

ORIGINAL ARTICLE

Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis

Angèle Gayet-Ageron,¹ Stephan Lautenschlager,² Béatrice Ninet,³ Thomas V Perneger,¹ Christophe Combescure¹

► Additional supplementary appendices are published online only. To view these files please visit the journal online (<http://dx.doi.org/10.1136/sextrans-2012-050622>).

¹Division of Clinical Epidemiology, Department of health and community medicine, University of Geneva & University Hospitals of Geneva, Geneva, Switzerland
²Outpatient Clinic for Dermatology and Venereology, Triemli Hospital, Zürich, Switzerland
³Department of Genetic Medicine and Laboratories, University of Geneva, Geneva, Switzerland

Correspondence to

Dr Angèle Gayet-Ageron, Division of Clinical Epidemiology, University Hospitals of Geneva, 6 Rue Gabrielle Perret-Gentil, 1211 Geneva 14, Switzerland; angele.gayet-ageron@hcuge.ch

Accepted 27 August 2012

ABSTRACT

Objective To systematically review and estimate pooled sensitivity and specificity of the polymerase chain reaction (PCR) technique compared to recommended reference tests in the diagnosis of suspected syphilis at various stages and in various biological materials.

Design Systematic review and meta-analysis.

Data sources Search of three electronic bibliographic databases from January 1990 to January 2012 and the abstract books of five congresses specialized in the infectious diseases' field (1999–2011). Search key terms included syphilis, *Treponema pallidum* or neurosyphilis and molecular amplification, polymerase chain reaction or PCR.

Review methods We included studies that used both reference tests to diagnose syphilis plus PCR and we presented pooled estimates of PCR sensitivity, specificity, and positive and negative likelihood ratios (LR) per syphilis stages and biological materials.

Results Of 1160 identified abstracts, 69 were selected and 46 studies used adequate reference tests to diagnose syphilis. Sensitivity was highest in the swabs from primary genital or anal chancres (78.4%; 95% CI: 68.2–86.0) and in blood from neonates with congenital syphilis (83.0%; 55.0–95.2). Most pooled specificities were ~95%, except those in blood. A positive PCR is highly informative with a positive LR around 20 in ulcers or skin lesions. In the blood, the positive LR was <10.

Conclusions The pooled values of LR showed that *T. pallidum* PCR was more efficient to confirm than to exclude syphilis diagnosis in lesions. PCR is a useful diagnostic tool in ulcers, especially when serology is still negative and in medical settings with a high prevalence of syphilis.

INTRODUCTION

Syphilis is a sexually-transmitted infection of concern worldwide. WHO estimated that 12 million new cases occurred in 1999,¹ of which 92% affect individuals in low-income countries. In most Western countries, syphilis is a cause of epidemics, particularly among men having sex with men.² When syphilitic chancres are present, there is also a higher risk of HIV transmission and acquisition.³

While the treatment of syphilis is simple, low cost and effective, its diagnosis remains challenging, particularly among asymptomatic cases (mainly latent forms), pregnant women and newborns, or in the early phase of the disease. The case definition of the US Centres for Disease

Control and Prevention (CDC)⁴ combines the presence of clinical signs or history with direct detection of *Treponema pallidum* in clinical specimens (primary, secondary and late syphilis) and/or reactive non-treponemal or treponemal tests. For chancres, a gold standard is the rabbit infectivity test, which is not routinely performed because it is time-consuming and expensive.^{5–6} When lesions are present, dark-field microscopy (DFM) or direct fluorescent-antibody is the most specific method to detect directly *T. pallidum*, but both require skilled laboratory staff and are also not widely available.⁵ When direct detection techniques are unavailable, serology testing combining a non-treponemal and a treponemal test is recommended. These provide a sensitivity ranging from 76% to 100% and specificity from 97% to 99%, depending on the syphilis stage, compared with direct detection of *T. pallidum* in clinical specimens.⁵

Today, there is an urgent need of a reliable, easy and cheap diagnostic test that would benefit patients in countries with limited resources. In the 1980s, the amplification of *T. pallidum* DNA by PCR has been proposed as an interesting, but costly, alternative.^{7–11} To be more powered to assess the diagnostic performance of PCR and to conclude on the best media to use, we reviewed all published studies using *T. pallidum* PCR in the diagnosis of syphilis and provided pooled estimates for sensitivity and specificity at various syphilis stages and in different biological specimens. We aimed also to identify factors that would explain any observed variability in the PCR diagnostic accuracy.

MATERIALS AND METHODS**Search strategy and selection criteria**

Two independent reviewers (AGA and SL) searched three databases (PubMed, Embase and Web of Science) and the abstract books from specialised conferences to identify published studies between January 1990 and January 2012. Details of the literature search and selection criteria are described in online supplementary appendix 1.

Quality assessment

We assessed the methodological quality of each selected study by using the quality assessment tool for diagnostic accuracy studies (QUADAS).^{12–13} Two independent assessments were made for studies published in English or French (by AGA and

SL), and one for reports in Czech¹⁴ and Russian.¹⁵ Details on the use of the QUADAS items are described in online supplementary appendix 1.

Data extraction

Three reviewers (AGA, SL, BN) screened abstracts of potentially relevant studies and applied the inclusion criteria. Reasons for exclusion were recorded and discrepancies were solved by consensus. Data extraction from the selected studies was done independently by two reviewers (AGA, SL) and two-by-two tables (PCR by reference test) were constructed for each study by syphilis stage and biological specimen tested. Data were verified for consistency and accuracy.

We collected the following data: author; journal; year of publication; study country; design; population characteristics; syphilis stage; PCR target; type of PCR; reference tests used to diagnose syphilis; purification of *T. pallidum* DNA during extraction; use of inhibitory controls; number of positive PCR among cases and number of negative PCR among controls (if available); number of cases and controls tested; and definitions of the reference test used for syphilis diagnosis. For blood specimens, we considered whole blood, serum or plasma as 'blood' and we collected separate data for each blood compartment. Early syphilis was defined as the stages of syphilis (primary, secondary and early latent syphilis) that occur within the first year after acquisition of infection. If data were missing or unclear, the corresponding author was contacted by email.

Data analysis

Due to the pathophysiology of the disease, we performed the analysis by syphilis stage and biological specimen. We calculated pooled estimates of the PCR sensitivity and specificity for all studies and, in a second step, only for studies using adequate reference tests by using the inverse variance method with random effects¹⁶ on the logit-transformed proportions. For studies providing both sensitivity and specificity, we estimated the pooled positive and negative likelihood ratios (LR+ and LR-, respectively) to assess the usefulness of PCR in the syphilis diagnosis. Heterogeneity was measured with the indicator I^2 which reflects the proportion of variance between studies that is due to factors other than chance.¹⁷ If I^2 was greater than 50% and the number of study was ≥ 10 , we explored potential heterogeneity factors defined a priori for the LR+ and LR-. We used meta-regression or Cochran tests to explore the between-strata heterogeneity only when at least two studies were available in each stratum. The impact of a potential publication bias was explored by using the Trim and Fill method when the number of studies was greater than 10. This method detects missing studies for the funnel plot to be symmetric and assesses the pooled result including the missing studies.¹⁸

All analyses were performed using Comprehensive Meta Analysis V.2 (Biostat, Englewood, New Jersey, USA) with the significance level set at 0.05.

RESULTS

Sixty-nine studies were retrieved by the systematic review. Two studies were not used in the meta-analysis: one that used aqueous humour from secondary syphilis with panuveitis to test for PCR, and one on syphilitic stillbirth that assessed the mothers' blood. The study flow chart is presented in online supplementary figure 1.

Studies' description

A summary of the 69 study characteristics by syphilis stage is presented in table 1 (see also online supplementary table 1). In less than half of all studies, the primary objective was the evaluation of the diagnostic performance of PCR. In the others, the primary objective was to describe the aetiology of genital ulcer diseases by using PCR (56.5%). In all studies, amplification was performed on native DNA and only two studies performed amplification on an initial RNA sample.¹⁵⁻¹⁹ The controls used to assess PCR specificity were mostly patients with genital ulcers caused by *Chlamydia trachomatis*, Herpes virus or *Haemophilus ducreyi*, but also aphthous ulceration and caustic or traumatic ulcerations. In the study population, 48.6% of patients were HIV-positive (29 studies). The use of antibiotics within the weeks prior to sampling was reported in 52% of studies (12/23). Overall, 17 studies mentioned controlling for inhibitory substances before PCR (25.8%).

Quality assessment and impact on pooled estimates

Most studies fulfilled the quality criteria related to bias (66.7%–95.6%, depending on the item). The study population was judged as representative of those who will receive the test in practice in 85.3% of studies. Finally, most studies fulfilled the items related to quality reporting (61.8%–86.8%, depending on the item). Syphilis diagnosis was established following the CDC recommendations in 66.7% of studies (table 1). In genital ulcer diseases (n=42 studies), DFM was used to diagnose syphilis in half of them. Pooled sensitivities and specificities were significantly lower in studies comparing PCR to inaccurate reference tests than those using adequate reference tests (table 2).

Pooled estimates of sensitivity and specificity

To correctly assess the diagnostic performance of PCR, we performed the meta-analysis on the 46 studies that used the recommended reference tests to diagnose syphilis. Pooled results are shown in table 2. Pooled sensitivities were very low for blood samples, except in studies of neonates with congenital syphilis (n=4). By blood compartment, depending on the stage, both serum and plasma provided higher sensitivities than whole blood, but not significantly (table 2). In contrast with blood, sensitivities were systematically higher than 70% for ulcer or skin lesions. In neurosyphilis, the sensitivity in cerebrospinal fluid (CSF) was close to 50%. We compared regular PCR with nested PCR, real-time PCR and multiplex PCR (data not shown). Sensitivities of nested PCR or regular PCR, depending on the stage and specimen, were higher than with real-time and multiplex PCR in all biological specimens and syphilis stages, without reaching statistical significance. Specificity was less often assessed than sensitivity. Globally, the pooled specificities were high (table 2). However, the pooled specificities for blood and CSF specimens were as low as 83% in some stages, while they were systematically higher than 95% for ulcer and skin lesions. Specificities remained comparable between the three blood compartments (table 2) and specificities were similar by the PCR method used.

In studies using adequate reference tests, a positive PCR in ulcer or skin lesions was highly suggestive of syphilis and 17.3–21.1 times as likely to occur in patients with early syphilis, as opposed to patients without. In contrast, a negative PCR was less useful and was 0.27–0.36 times as likely to occur in patients with early syphilis, as opposed to those without (table 2). In studies using adequate reference tests in the ulcers or skin lesions from early syphilis, we found significantly

Table 1 Summary of the 69 principal study characteristics by syphilis stage and in all stages

	Primary	Secondary	Early	Latent	Neurosyphilis	Congenital	All stages
Number of studies	30	25	21	12	10	7	69*
Continent, n (% per stage)							
Africa	6 (20.0%)	0 (0.0%)	6 (28.6%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	13
Asia	2 (6.7%)	1 (4.0%)	5 (23.8%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	8
Eastern Europe	4 (13.3%)	5 (20.0%)	0 (0.0%)	3 (25.0%)	0 (0.0%)	0 (0.0%)	5
Oceania	0 (0.0%)	0 (0.0%)	2 (9.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
North America	9 (30.0%)	6 (24.0%)	2 (9.5%)	3 (25.0%)	3 (30.0%)	6 (85.7%)	16
South America	0 (0.0%)	2 (8.0%)	3 (14.3%)	0 (0.0%)	1 (10.0%)	1 (14.3%)	4
Western Europe	9 (30.0%)	11 (44.0%)	3 (14.3%)	5 (41.7%)	5 (50.0%)	0 (0.0%)	20
Specimen, n (% per stage)							
Blood	10 (33.3%)	13 (52.0%)	2 (9.1%)	10 (83.3%)	1 (11.1%)	6 (85.7%)	42
Ulcer/lesion	27 (90.0%)	18 (72.0%)	20 (90.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	65
Cerebrospinal fluid	1 (3.3%)	1 (4.0%)	2 (9.1%)	2 (16.7%)	8 (88.8%)	3 (42.9%)	17
Aqueous humour	0 (0.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Placenta	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (14.3%)	1
Amniotic fluid	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (28.6%)	2
Type of PCR, n (% per stage)							
Multiplex PCR	9 (30.0%)	1 (4.0%)	15 (71.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	25
Standard PCR	13 (43.3%)	12 (48.0%)	4 (19.0%)	7 (58.3%)	8 (80.0%)	7 (100%)	44
Real-time PCR	4 (13.3%)	5 (20.0%)	1 (4.8%)	2 (16.7%)	1 (10.0%)	0 (0.0%)	13
Nested PCR	4 (13.3%)	7 (28.0%)	1 (4.8%)	3 (25.0%)	1 (10.0%)	0 (0.0%)	16
PCR target, n (% per stage)							
<i>tpp47</i> gene	19 (63.3%)	13 (52.0%)	16 (76.2%)	6 (50.0%)	7 (70.0%)	4 (57.1%)	65
<i>polA</i> gene	7 (23.3%)	9 (36.0%)	3 (14.3%)	3 (25.0%)	0 (0.0%)	2 (28.6%)	24
<i>bmp</i> gene	0 (0.0%)	0 (0.0%)	2 (9.5%)	1 (8.3%)	1 (10.0%)	0 (0.0%)	4
<i>tmpC</i> gene	1 (3.3%)	1 (4.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	3
16SrRNA gene	2 (6.6%)	1 (4.0%)	1 (4.8%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	5
<i>tmpA</i> gene	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	1
Combination of targets	2 (6.6%)	1 (4.0%)	0 (0.0%)	2 (16.7%)	0 (0.0%)	1 (14.3%)	6
Number of patients							
Total	4417	1398	2885	534	397	217	9848
Cases	1516	604	762	494	205	116	3697
Controls	2901	794	2123	40	192	101	6151
% Male	73.4%	76.5%	77.8%	70.2%	80.5%	NA	75.3%
Range of median age, years	26-37	31-42	25-37	35-37	37	NA	23-42
Accurately reported reference test	19 (63.3%)	18 (72.0%)	12 (57.1%)	10 (83.3%)	9 (90.0%)	7 (100%)	46 (66.7%)*

*The number of studies exceeds the sum of the stages as one study could report data on several stages.

higher LR+ and lower LR- compared with those using inadequate reference tests (table 2). Regarding the usefulness of PCR in congenital syphilis diagnosis, the LR+ was higher than the threshold of 10 in the CSF of newborns while LR+ was lower in the blood.

Publication bias

A potential publication bias was detected for some pooled LR (data not shown), but it did not change the conclusions of the meta-analysis.

Factors explaining heterogeneity

Sources of heterogeneity were explored for LR- in ulcers from primary syphilis and for LR+ plus LR- in lesion swabs from early syphilis. We did not find any association between LR- and LR+ depending on the stage, the year of publication or the gross national income (data not shown). The only factor that explained heterogeneity in the LR+ of lesion swabs from early syphilis was the PCR target: polymerase A gene (*polA* gene) provided a significantly higher LR+ than the 47KD lipoprotein gene (*tpp47*), but both provided excellent LR+: 41.0 (25.3–66.6) versus 14.8 (8.9–24.5), respectively ($p=0.004$). The heterogeneity in

the LR- of lesion swabs from early syphilis was explained by the type of PCR with a lower LR- when standard PCR was used compared with multiplex PCR: 0.31 (0.22–0.45) and 0.51 (0.44–0.59), respectively ($p=0.02$).

DISCUSSION

This meta-analysis indicates that, when the reference tests are adequate, the sensitivity of *T. pallidum* PCR is moderate, while its specificity is very good. However, the diagnostic performance varied with the biological specimen tested, especially for sensitivity. The best performance was found in ulcers from primary syphilis and, more generally, symptomatic lesions provided higher sensitivities than blood or even CSF. In the blood, PCR sensitivity was higher in plasma or serum than in whole blood. Regarding the PCR method, nested PCR or regular PCR was more sensitive than multiplex or real-time PCR in all syphilis stages and specimens. The inadequacy of reference tests recommended by the CDC was also associated with lower sensitivity. In addition, the PCR target and the type of PCR also explained heterogeneity in the subgroup of studies that used adequate reference tests. PCR targeting the *polA* gene provided

Table 2 Pooled sensitivities, specificities and LRs (positive and negative) of *Treponema pallidum* PCR (random effects) with their heterogeneity (I^2), by syphilis stage and biological specimen tested

Stage/specimen	Sensitivity			Specificity			Positive LR			Negative LR		
	n	(95% CI)	I^2	n	(95% CI)	I^2	n	(95% CI)	I^2	n	(95% CI)	I^2
Primary syphilis												
Blood*												
Adequate reference tests	8	37.7 (18.0 to 62.4)	66.9%	4	95.7 (84.3 to 98.9)	0.0%	3	5.4 (1.0 to 28.5)	0.0%	3	0.78 (0.63 to 0.96)	0.0%
Whole blood	6	36.1 (24.2 to 50.0)		4	95.7 (84.3 to 98.9)							
Serum	3	50.2 (27.2 to 73.2)		1	93.7 (46.1 to 99.6)							
Plasma	2	39.4 (19.3 to 63.8)		–	–							
Inadequate reference tests	1	5.6 (0.3 to 50.5)	–	–	–	–	–	–	–	–	–	–
Ulcer†												
Adequate reference tests	15	78.4 (68.2 to 86.0)	75.4%	11	96.6 (95.5 to 97.5)	0.0%	10	21.0 (15.5 to 28.4)	0.0%	10	0.27 (0.18 to 0.40)	82.7%
Inadequate reference tests	11	42.2 (31.8 to 53.3)	79.6%	20	96.7 (94.3 to 98.1)	50.1%	9	11.1 (5.6 to 21.9)	61.0%	9	0.70 (0.60 to 0.82)	85.1%
Secondary syphilis												
Blood*												
Adequate reference tests	9	52.2 (37.3 to 66.7)	71.1%	4	83.3 (51.1 to 96.0)	49.3%	4	2.6 (0.9 to 7.6)	25.2%	4	0.66 (0.50 to 0.87)	0.0%
Whole blood	7	54.2 (41.0 to 66.8)		3	93.2 (72.2 to 98.6)							
Serum	3	42.4 (11.4 to 80.8)		2	93.6 (87.4 to 96.8)							
Plasma	3	55.3 (16.2 to 88.9)		1	91.7 (37.8 to 99.5)							
Inadequate reference tests	2	34.4 (0.7 to 97.6)	77.1%	1	93.7 (87.4 to 97.0)	–	1	12.4 (5.3 to 29.3)	–	1	0.18 (0.01 to 2.24)	–
Lesion swabs‡												
Adequate reference tests	13	72.0 (57.1 to 83.2)	64.7%	9	96.3 (92.1 to 98.3)	0.0%	9	17.3 (8.1 to 37.0)	0.0%	9	0.36 (0.24 to 0.55)	66.7%
Inadequate reference tests	4	66.2 (49.5 to 79.6)	28.0%	2	97.6 (71.6 to 99.8)	75.6%	2	27.9 (1.3 to 58.8)	79.0%	2	0.35 (0.18 to 0.69)	68.0%
Early syphilis												
Blood*												
Adequate reference tests	19	41.6 (28.5 to 56.0)	79.9%	7	94.8 (86.0 to 98.2)	0.0%	6	6.4 (2.0 to 20.0)	0.0%	6	0.73 (0.61 to 0.87)	0.0%
Whole blood	13	41.2 (26.5 to 57.6)		7	94.8 (86.0 to 98.2)							
Serum	9	42.6 (24.8 to 62.5)		2	92.8 (62.7 to 99.0)							
Plasma	6	41.1 (20.2 to 65.7)		1	91.7 (37.8 to 99.5)							
Inadequate reference tests	1	83.3 (19.4 to 99.0)	–	1	93.7 (87.4 to 97.0)	–	1	12.4 (5.3 to 29.3)	–	1	0.18 (0.01 to 2.24)	–
Lesion swabs§												
Adequate reference tests	36	75.9 (68.5 to 82.0)	79.0%	26	96.5 (95.0 to 97.6)	43.7%	25	21.1 (13.2 to 33.5)	62.9%	25	0.32 (0.25 to 0.41)	84.3%
Inadequate reference tests	18	50.3 (40.5 to 60.1)	85.6%	16	95.5 (92.9 to 97.2)	70.6%	16	9.2 (6.0 to 14.2)	60.6%	16	0.58 (0.50 to 0.68)	86.7%
Neurosyphilis¶												
CSF	8	47.4 (31.7 to 63.7)	75.5%	4	85.0 (39.9 to 98.0)	89.9%	4	4.5 (0.9 to 23.6)	91.1%	4	0.54 (0.27 to 1.07)	69.1%
Latent syphilis¶												
Blood												
Whole blood	13	31.2 (22.4 to 41.5)	66.8%	4	83.5 (22.7 to 98.9)	78.5%	2	1.8 (0.0 to 304.3)	89.5%	2	1.41 (0.08 to 25.64)	87.8%
Serum	6	20.2 (9.3 to 38.4)		3	72.1 (8.6 to 98.6)							
Serum	3	20.9 (1.6 to 81.2)		1	97.6 (71.3 to 99.9)							
Plasma	5	39.4 (33.8 to 45.4)		–	–							
CSF	3	6.0 (3.6 to 10.0)	0.0%	1	87.5 (26.6 to 99.3)	0.0%	–	–	–	–	–	–
Congenital syphilis¶												
Blood												
Blood	4	83.0 (55.0 to 95.2)	40.3%	3	88.8 (79.9 to 94.1)	0.0%	3	8.1 (4.4 to 15.2)	0.0%	3	0.11 (0.04 to 0.33)	0.0%
CSF	3	62.2 (42.2 to 78.8)	6.2%	3	96.4 (89.5 to 98.8)	0.0%	3	17.5 (5.6 to 55.0)	0.0%	3	0.44 (0.28 to 0.67)	0.1%

*In blood, the estimates and LR are not reported among studies using inadequate reference tests due to small numbers (<3).

†Comparison of LR+ in ulcers between adequate and inadequate reference tests provided significant difference with $p=0.01$. Comparison of LR– was also significantly different with $p=0.002$.

‡Comparison of LR+ then LR– in skin lesions between adequate and inadequate reference tests provided a non-significant difference.

§Comparison of LR+ in skin lesions between adequate and inadequate reference tests was significantly different with $p=0.006$ as the comparison of LR– ($p=0.003$).

¶For neurosyphilis, latent and congenital syphilis, all studies used the adequate reference tests.

CSF, cerebrospinal fluid; LR, likelihood ratio.

higher LR+ than those targeting the 47KD lipoprotein gene (*tpp47*). Regular PCR provided lower LR- than multiplex PCR.

Some studies have shown that PCR sensitivities and specificities were higher in blood compared with ulcer and chancre^{14 20–27} and this result was confirmed by our meta-analysis. The potential explanations are that DNA extraction from blood provided a lower yield than skin lesions,^{24 27} thus postulating a higher *T. pallidum* load in skin lesions than in blood,²⁸ but also that substances may be present in whole blood and inhibit PCR.²⁹ Nonetheless, clinical lesions are only present in the early symptomatic phase of the disease. In the case of asymptomatic disease, even if the ear lobe was proven to provide the highest DNA yield, these results were described in only one study³⁰ and blood remains the easiest media to use. When stratified by blood compartment, sensitivities were higher in plasma or serum than in whole blood and this confirms the results from previous studies on a larger number of cases.^{20 30}

Regarding the PCR technique itself, some authors suggested that its lack of sensitivity was related to non-specific inhibitory substances in whole blood that could be controlled when extracting DNA.⁸ Apart from DNA extraction, *T. pallidum* genes targeted and the PCR method used might also explain the great heterogeneity of PCR sensitivity. Castro *et al*³⁰ compared the 47KD lipoprotein gene (*tpp47*) with *poA* gene and a combination of both on the same biological samples. They showed that PCR targeting 47KD lipoprotein gene (*tpp47*) was the most sensitive but we did not find any difference. They also worked on paired data and used the same material to compare PCR targets and this might have increased the power of the study. Regarding the PCR method used, we did not find significant differences in their diagnostic performance. Multiplex PCR has the advantage of identifying multiple infectious agents, but already showed a lower sensitivity to detect *T. pallidum*.³¹ By contrast, nested PCR increases sensitivity by amplifying a secondary target within the first run product.²⁴ Finally, real-time PCR presents the advantages to provide rapid and quantitative results and also to reduce the likelihood of contamination. To our knowledge, no previous study has compared the performance of different PCR methods in syphilis diagnosis and meta-analysis allows making such comparisons on a larger number of cases.

The LR+ was above the threshold value of 10 that is considered as the lower limit of clinical usefulness for some authors, but the LR was above the threshold of 0.10 considered as the higher limit to rule out the diagnosis.³² However, we should not interpret the LR in isolation. The pretest probability of the disease should also be considered when estimating the post-PCR probability of syphilis. Figure 1 illustrates the post-test probability as a function of the pretest probability using the LR obtained in ulcers from primary syphilis. When the pretest probability of syphilis is 16%, the risk of having syphilis reaches 80% if the PCR is positive in ulcers, and 5% if the PCR is negative. For syphilis prevalence above 16%, a positive PCR increases the post-test probability above 80%. In contrast, below 16%, a negative PCR test is informative, as it pushes the probability of disease to very low values.

Our study has several limitations. First, we were not able to test the heterogeneity factors in all subgroups due to the small number of studies available. Although HIV status may influence reference tests,³³ disaggregated data to explore HIV as a potential heterogeneity factor were insufficient. Second, regarding the PCR technique itself, some hypotheses were not tested due to lack of information. For instance, DNA




Figure 1 Post-test probabilities (with 95% CIs) of *Treponema pallidum* PCR for different values of syphilis prevalence taking a likelihood ratio (LR)+ of 21.0 (15.5–28.4) and a LR- of 0.27 (0.18–0.40). Horizontal dashed lines represent desired levels of the post-test probabilities to rule-out (level 0.05) and to rule-in (level 0.80) syphilis diagnosis.

extraction and purification can be done either manually or automatically and this could also modify PCR sensitivity.⁹ It is also important to test systematically for the presence of substances that inhibit PCR³⁴ and this was done in a small proportion of studies, but we were unable to obtain the information for the remaining reports. Furthermore, the amplification procedure needs to be done at least in triplicate in order to achieve acceptable reproducibility,³⁵ but none of the selected studies reported using this method. Finally, the gold standard to diagnose syphilis remains animal infectivity testing or rabbit infectivity test, but this is not routinely performed.⁵ As an alternative, the CDC recommends the use of DFM or direct fluorescent-antibody for the direct detection of *T. pallidum* in clinical specimens from early syphilis. DFM is a reference test in the diagnosis of syphilis, but not the gold standard. As a consequence, the assessment of the diagnostic performance of PCR may be biased.³⁶

In conclusion, this meta-analysis confirmed that PCR could be a useful tool in the diagnosis of ulcer or chancres following risky sexual behaviour, especially when serology is not yet reactive or in a large number of regions when DFM is not available. We showed also a large heterogeneity of diagnostic values between studies and the diagnostic performance of PCR varied largely according to the biological specimen. The summary of the published diagnostic values by specimen and clinical stage of syphilis may help to guide future clinical practice.

Key messages

- ▶ In this meta-analysis, we summarised the published diagnostic values of *Treponema pallidum* PCR (TpPCR) by clinical stage and biological specimen.
- ▶ Sensitivities were 31.2% in blood from latent syphilis, 75.9% in ulcers from early syphilis, and specificities were 83.5% and 96.5%, respectively.
- ▶ The pooled values of likelihood ratios showed that TpPCR was more efficient to confirm than to exclude syphilis diagnosis in lesions.

Acknowledgements We thank Ms Rosemary Sudan for editorial assistance and Dr Youri Popowski for his help in the translation of the Russian publication. We thank also all the following authors for their kind collaboration (R. Castro, J. Gatrix, IF. Hoffman and the University North Carolina Group, K. Nagy, MA. Kingston, H. Liu, IM. Mackay, I. Martin, GT. Noordhoek, N. O'Farrell, G. Riedner, AE. Singh, W. Sturm, M. Sutton, V. Woznicová).

Contributors AG-A coordinated the work, searched relevant abstracts, assessed published work, extracted data, and analysed and interpreted the data. SL searched relevant abstracts, assessed published work and extracted data. BN searched relevant abstracts. CC analysed and interpreted the data. TVP takes responsibility for the integrity of the data and the accuracy of the data analysis. AGA wrote the paper with important contributions from SL, BN, CC and TVP.

Funding None.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. WHO. *Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates*. Geneva: World Health Organization, 2001. http://www.who.int/hiv/pub/sti/en/who_hiv_aids_2001.02.pdf.
2. Torrone EA, Bertolli J, Li J, *et al*. Increased HIV and primary and secondary syphilis diagnoses among young men—United States, 2004–2008. *J Acquir Immune Defic Syndr* 2011;**58**:328–35.
3. Zetola NM, Bernstein KT, Wong E, *et al*. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. *J Acquir Immune Defic Syndr* 2009;**50**:546–51.
4. CDC. *Case definitions for infectious conditions under public health surveillance*. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1997;**46**:1–55.
5. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. *Clin Microbiol Rev* 1995;**8**:1–21.
6. Liu H, Rodes B, Chen CY, *et al*. New tests for syphilis: rational design of a PCR method for detection of *Treponema pallidum* in clinical specimens using unique regions of the DNA polymerase I gene. *J Clin Microbiol* 2001;**39**:1941–6.
7. Burstain JM, Grimprel E, Lukehart SA, *et al*. Sensitive detection of *Treponema pallidum* by using the polymerase chain reaction. *J Clin Microbiol* 1991;**29**:62–9.
8. Grimprel E, Sanchez PJ, Wendel GD, *et al*. Use of polymerase chain reaction and rabbit infectivity testing to detect *Treponema pallidum* in amniotic fluid, fetal and neonatal sera, and cerebrospinal fluid. *J Clin Microbiol* 1991;**29**:1711–18.
9. Noordhoek GT, Wolters EC, de Jonge ME, *et al*. Detection by polymerase chain reaction of *Treponema pallidum* DNA in cerebrospinal fluid from neurosyphilis patients before and after antibiotic treatment. *J Clin Microbiol* 1991;**29**:1976–84.
10. Sanchez PJ, Wendel GD Jr, Grimprel E, *et al*. Evaluation of molecular methodologies and rabbit infectivity testing for the diagnosis of congenital syphilis and neonatal central nervous system invasion by *Treponema pallidum*. *J Infect Dis* 1993;**167**:148–57.
11. Wicher K, Noordhoek GT, Abbruscato F, *et al*. Detection of *Treponema pallidum* in early syphilis by DNA amplification. *J Clin Microbiol* 1992;**30**:497–500.
12. Whiting P, Rutjes AW, Reitsma JB, *et al*. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003;**3**:25.
13. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. *BMC Med Res Methodol* 2005;**5**:19.
14. Flasarova M, Smajs D, Matejkova PW, *et al*. Molecular detection and subtyping of *Treponema pallidum* subsp. *pallidum* in clinical specimens. *Epidemiologie, Mikrobiologie, Immunologie* 2006;**55**:105–11.
15. Rodionova EN, Gushchin AE, Shipulin GA, *et al*. Detection of *Treponema pallidum* DNA and RNA in clinical material from patients with syphilis at different stages. *Zh Mikrobiol Epidemiol Immunobiol* 2003;**3**:43–50.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;**7**:177–88.
17. Higgins JP, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60.
18. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;**56**:455–63.
19. Marra CM, Maxwell CL, Smith SL, *et al*. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. *J Infect Dis* 2004;**189**:369–76.
20. Castro R, Prieto E, Aguas MJ, *et al*. Molecular subtyping of *Treponema pallidum* subsp. *pallidum* in Lisbon, Portugal. *J Clin Microbiol* 2009;**47**:2510–12.
21. Gayet-Ageron A, Ninet B, Toutous-Trellu L, *et al*. Assessment of a real-time PCR test to diagnose syphilis from diverse biological samples. *Sex Transm Inf* 2009;**85**:264–9.
22. Heroldova M, Woznicova V. *PaIA* PCR in syphilis diagnostic. *Clin Microbiol Infect* 2004;**10**:643.
23. Kouznetsov AV, Weisenseel P, Trommler P, *et al*. Detection of the 47-kilodalton membrane immunogen gene of *Treponema pallidum* in various tissue sources of patients with syphilis. *Diagn Microbiol Infect Dis* 2005;**51**:143–5.
24. Martin IE, Tsang RS, Sutherland K, *et al*. Molecular characterization of syphilis in patients in Canada: azithromycin resistance and detection of *Treponema pallidum* DNA in whole-blood samples versus ulcerative swabs. *J Clin Microbiol* 2009;**47**:1668–73.
25. Sutton MY, Liu H, Steiner B, *et al*. Molecular subtyping of *Treponema pallidum* in an Arizona County with increasing syphilis morbidity: Use of specimens from ulcers and blood. *J Infect Dis* 2001;**183**:1601–6.
26. Tipple C, Hanna MO, Hill S, *et al*. Getting the measure of syphilis: qPCR to better understand early infection. *Sex Transm Infect* 2011;**87**:479–85.
27. Peng RR, Wang AL, Li J, *et al*. Molecular typing of *Treponema pallidum*: a systematic review and meta-analysis. *PLoS Negl Trop Dis* 2011;**5**:e1273.
28. Salazar JC, Rathi A, Michael NL, *et al*. Assessment of the kinetics of *Treponema pallidum* dissemination into blood and tissues in experimental syphilis by real-time quantitative PCR. *Infect Immun* 2007;**75**:2954–8.
29. Al-Soud WA, Radstrom P. Purification and characterization of PCR-inhibitory components in blood cells. *J Clin Microbiol* 2001;**39**:485–93.
30. Castro R, Prieto E, Aguas MJ, *et al*. Detection of *Treponema pallidum* sp *pallidum* DNA in latent syphilis. *Int J STD AIDS* 2007;**18**:842–531.
31. Morse SA, Trees DL, Htun Y, *et al*. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in lesotho: Association with human immunodeficiency virus infection. *J Infect Dis* 1997;**175**:583–9.
32. Jaeschke R, Guyatt GH, Sackett D, for the Evidence-Based Medicine Working Group. User's guides to the medical literature. III. How to use an article about the diagnostic test. B. What are the results and will they help me in caring my patients? *JAMA* 1994;**271**:703–7.
33. Augenbraun MH, DeHovitz JA, Feldman J, *et al*. Biological false-positive syphilis test results for women infected with human immunodeficiency virus. *Clin Infect Dis* 1994;**19**:1040–4.
34. Orle KA, Gates CA, Martin DH, *et al*. Simultaneous PCR detection of *Haemophilus ducreyi*, *Treponema pallidum*, and herpes simplex virus types 1 and 2 from genital ulcers. *J Clin Microbiol* 1996;**34**:49–54.
35. Ahmed A, Engelberts MF, Boer KR, *et al*. Development and validation of a real-time PCR for detection of pathogenic leptospira species in clinical materials. *PLoS One* 2009;**4**:e7093.
36. Valenstein PN. Evaluating diagnostic tests with imperfect standards. *Am J Clin Pathol* 1990;**93**:252–8.



Sensitivity, specificity and likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis

Angèle Gayet-Ageron, Stephan Lautenschlager, Béatrice Ninet, Thomas V Perneger and Christophe Combescure

Sex Transm Infect published online September 28, 2012

Updated information and services can be found at:
<http://sti.bmj.com/content/early/2012/09/27/sextrans-2012-050622>

These include:

- Supplementary Material** Supplementary material can be found at:
<http://sti.bmj.com/content/suppl/2012/09/27/sextrans-2012-050622.DC1.html>
- References** This article cites 35 articles, 20 of which you can access for free at:
<http://sti.bmj.com/content/early/2012/09/27/sextrans-2012-050622#BIBL>
- Email alerting service** Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.
-

Topic Collections

Articles on similar topics can be found in the following collections

[Syphilis](#) (783)
[Drugs: infectious diseases](#) (3158)
[Infection \(neurology\)](#) (46)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>